Other lipid agents × lipids

TrialThe Journal of clinical endocrinology and metabolism2015

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

Harold Bays et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 355 people · 2015

No range given

Reported lower lipids, no range given

−54.0percentage points

As reported

difference −54.0 %, no interval

One number in the abstract

the abstract, start to end

reduced LDL-C levels by 44.1% and 54.0% (P < .001 vs all comparators);

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Lipids
−54.0
StatinsPCSK9 inhibitorsOther lipid agentsLipids
1 / 3

92 papers cite itlatest 60 shown

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 26030325